Treace Medical Concepts announced it will highlight new product innovations and present new interim data for the ALIGN3D and MTA3D clinical studies at the American Orthopaedic Foot & Ankle Society (AOFAS) annual meeting.

Treace will feature clinical data and several new technologies at its AOFAS exhibit booth and host surgeon training events on these innovations:

• Nanoplasty MIS 3D bunion correction: The procedure was designed to accelerate surgeon access to 3D MIS osteotomies and is done through a single 1.5 cm hidden incision on the side of the foot. Nanoplasty is a system for rapid MIS adoption through a guided saw cut, instrumentation to dial in the 3D correction, and the predictable strength of locking fixation.
• Percuplasty percutaneous 3D bunion correction: This is the company’s second system designed to speed access to MIS osteotomies. It’s performed through 0.5 cm percutaneous incisions and features self-drilling screw implants and instruments that dial in the 3D correction and accurately target implant placement.
• Percuplasty MIS power system: The specialized, scalable “plug and play” power drill operates the single-use cutting burrs used in the Percuplasty procedure as well as a range of other minimally invasive procedures through the foot.
• SpeedMTP MTP fusion system: This extends the benefits of the company’s SpeedPlate tech to offer a fusion option to address bunion patient with arthritic great toe (MTP) joints. It combines the SpeedPlate dynamic compression tech with Fastpitch locking screws to deliver an ultra-low profile implant.
• Intelliguide PSI: The platform technology provides personalized, 3D-printed cut guides for Lapiplaty and Adductoplasty procedures. Intelliguide generates intelligent pre-op 3D planning and titanium 3D-printed guides with integrated 3D correction.
• Micro-Lapiplasty minimally invasive system: This features specialized MIS instrumentation and the new SpeedPlate MicroQuad implant.

New complementary technologies will also be featured, including the SpeedAkin Anatomic Compression Implant used in Akin osteotomy procedures, as well biologics commonly used in foot and ankle fusion procedures, including CortiFuse flowable cortical fibers and Treace’s line of procedure-specific Allograft Wedges.

ALIGN3D Lapiplasty clinical study presentation

The ALIGN3D Lapiplasty clinical study podium presentation, “Four- and Five- Year Analysis of a Prospective Multicenter Study Assessing Radiographic Recurrence and Patient Outcomes Following Triplanar Tarsometatarsal Arthrodesis with Early Weightbearing”, will be presented by Daniel Farber, MD, Lehigh Valley Orthopedic Institute (Bethlehem, Pa.)

The study included interim data from the five-year ALIGN3D clinical study of 146 of 173 total patients treated within at least four years of follow-up. There was a return to weight bearing in a walking boot in an average 8.4 days, and low radiographic recurrence rates at 48 months.

MTA3D Adductoplasty clinical study presentation

Interim data from the MTA3D Adductoplasty study will also be presented AOFAS in a poster presentation titled, “Interim 1-Year Analysis of a Multicenter Prospective Study Assessing Radiographic and Patient Outcomes Following Combined Metatarsus Adductus and Hallux Valgus Correction with Early Weightbearing” by Mark Easley, MD of Duke University (Durham, N.C.)

The presentation will feature interim analysis of 33 of 60 patients treated with at least one-year follow-up. Data showed 7.9 days average return to weight bearing and clinically significant improvement in radiographic measures of both midfoot and 3D bunion deformity at 12 months.

“We are excited to highlight the full commercial release of our expanded bunion portfolio at AOFAS, which now provides surgeons with best-in-class solutions to address the entire spectrum of bunion surgery,” said John T. Treace, CEO, founder, and chairman of Treace. “With the addition of Nanoplasty, Percuplasty, SpeedMTP, and IntelliGuide PSI, we are building on the success of Lapiplasty and Adductoplasty to advance our company’s focused mission to improve surgical outcomes for bunion patients. We also look forward to sharing compelling clinical evidence from prospective, multicenter studies that continues to differentiate our flagship Lapiplasty and Adductoplasty procedures.”